Xenoport, Inc.

Theravance Biopharma R&d IP, LLC

Genentech, Inc.

Manshiu Leung

Fritz Blatter

Venkat R Thalladi

Kenneth C Cundy

Sami Karaborni

Lawrence Emerson Fisher

Chen Mao

Karthik Nagapudi

Hao Zhang

Shaoling Li

Yun Mo

Srikonda Sastry

Balaji V Kadri

Paul E Stach

Yuan Liu

David J Kidney

Ramachandran Radhakrishnan

Rajendra S Tandale

Shuai Wang

Wei Zhang

Christine Czauderna

Markus Frieser

Roland Muller

Ludwig Pilsl

The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(&#x3b1;-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.

GABA analog prodrug sustained release oral dosage forms

Crystalline (2R)-2-phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate, hydrate, methods of making the hydrate, pharmaceutical compositions containing the hydrate, and methods of using the hydrate to treat diseases or disorders such as Parkinson's disease are provided.

Levodopa prodrug mesylate hydrate

Growing community of inventors

Daly City, CA, United States of America

Manshiu Leung